A Study in Subjects With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Antibody as a Single Agent and in Combination With Balstilimab, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04156100
• Other study ID #: C-900-01
• Status: Terminated
• Phase: Phase 1
• Start date: December 10, 2019
• Est. completion date: September 29, 2021

Study information

• Verified date: February 2022
• Source: Agenus Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors.

Description:

This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors. This Phase 1 study will be conducted in an accelerated titration (for the first 2 single agent AGEN1223 dosing cohorts) and standard 3+3 dose escalation format. Study drug treatment will be administered on Day 1 of each 3-week cycle for up to 2 years or until any progressive disease (PD) or unacceptable toxicity is reported. The timing of the administration of doses may be adjusted for management of adverse events (AEs). The safe starting dose of AGEN1223 single-agent will be at the estimated minimally anticipated biological effect level. The treatment phase is divided into 3-week cycles with associated evaluations and procedures that must be performed at specific time points. Tumor assessments will be conducted every 6 weeks (±7 days) from first dose until treatment discontinuation or disease progression. In subjects that discontinue treatment for reasons other than PD, imaging will continue until PD or initiation of a new therapy. If the subject discontinues treatment because of PD, imaging may be performed if clinically beneficial or if deemed necessary by the investigator until the initiation of new antineoplastic therapy. This must be approved by the Sponsor. A Safety Monitoring Committee (SMC) will be established to assess safety and determine dose escalation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 19
• Est. completion date: September 29, 2021
• Est. primary completion date: April 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study specific procedures (participation in genetic testing is optional).

2. Greater than or equal to 18 years of age

3. Histologically or cytologically confirmed diagnosis of an advanced solid tumor for which no standard therapy is available or standard therapy has failed.

4. Measurable disease on baseline imaging based on RECIST 1.1.

5. Life expectancy of at least 3 months and an ECOG performance status of 0 or 1 (Appendix A).

6. Adequate organ function as indicated by the following laboratory values:

• Adequate hematological function, defined as ANC =1.5 × 109/L, platelet count =100 × 109/L, and hemoglobin =8 g/dL without recent transfusion (defined as a transfusion that has occurred within 2 weeks of the hemoglobin measurement).
• Adequate hepatic function based by a total bilirubin level =1.5 × the institutional upper limit of normal (IULN), AST level =2.5 × IULN, ALT level =2.5 × IULN.
• Adequate renal function defined as creatinine =1.5 × IULN or measured or calculated creatinine clearance >40 mL/min per institutional standard. Assessment methods should be recorded.
• Adequate coagulation defined by international normalized ratio or prothrombin time =1.5 × IULN and activated partial thromboplastin time =1.5 × IULN (unless the subject is receiving anticoagulant therapy).

7. No history of prior or concomitant malignancy that requires other active treatment.

8. Subjects must provide a sufficient and adequate FFPE tumor tissue sample (fresh biopsy) collected within 28 days before the first dose from a site not previously irradiated and to agree to a mandatory on-treatment biopsy if clinically feasible.

9. Female subjects of child-bearing potential must have a negative serum pregnancy test at screening (within 72 hours of first dose of study medication). Subjects with tumors producing human chorionic gonadotropin and gestational trophoblastic tumor do not need a serum pregnancy test, and absence of pregnancy should be documented by the Principal Investigator (PI) based on clinical and radiological assessments as needed.

Non-childbearing potential is defined as:

• =45 years of age and has not had menses for greater than 1 year,
• Amenorrheic for =2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon prestudy (screening) evaluation,
• Status is post-hysterectomy, oophorectomy, or tubal ligation.

10. Female subjects of child-bearing potential must be willing to use highly effective contraceptive measures starting with the screening visit through 90 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the subject.

11. Male subjects with a female partner(s) of child-bearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 90 days after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner. Note: Abstinence is acceptable if this is the established and preferred contraception method for the subject.

12. Willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

1. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 3 weeks of the first dose of current study drug.

2. Any relevant bispecific antibody, and/or anti-PD-1/PDL1 agents. For selected indication cohorts, prior treatment may be permitted after discussion with the Sponsor. Prior therapy with PD-1/PDL1 inhibitor may be allowed in agreement with the Sponsor.

3. Received prior systemic cytotoxic chemotherapy, biological therapy, radiotherapy, or major surgery within 3 weeks prior to first dose of study drug; a 1-week washout is permitted for palliative radiation to non-central nervous system (CNS) disease with Sponsor approval.

4. Persisting toxicity with Grade >1 severity related to prior therapy based on NCI-CTCAE Version 5.0. Note: Sensory neuropathy and alopecia of Grade =2 are acceptable.

5. Expected to require any other form of systemic or localized antineoplastic therapy while on study (including maintenance therapy with another agent, radiation therapy, and/or surgical resection).

6. Known severe hypersensitivity reactions (NCI-CTCAE Grade =3) to fully human monoclonal antibodies, or severe reaction to immuno-oncology agents, such as colitis or pneumonitis, requiring treatment with steroids, or has a history of interstitial lung disease (ILD), any history of anaphylaxis, or uncontrolled asthma.

7. Receiving systemic corticosteroid therapy 1 week prior to the first dose of study drug or receiving any other form of systemic immunosuppressive medication. Note: Corticosteroid use as a premedication for IV contrast allergies/reactions is allowed. Subjects who are receiving daily corticosteroid replacement therapy are an exception to this rule. Daily prednisone at doses of up to 7.5 mg or equivalent hydrocortisone doses are examples of permitted replacement therapy. Use of inhaled or topical corticosteroids is permitted.

8. CNS tumor, metastasis, and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period or identified prior to consent. Note: Subjects with history of brain metastases that have been treated may participate provided they show evidence of stable supra-tentorial lesions at screening (defined as 2 brain images, both of which are obtained after treatment to the brain metastases; these imaging scans should both be obtained =4 weeks apart). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have returned to baseline or resolved. Any steroids administered as part of this therapy must be completed =3 days prior to the first dose of study medication.

9. Active or history of autoimmune disease that has required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Note: Subjects with diabetes type 1, vitiligo, psoriasis, and hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

10. Allogeneic tissue/solid organ transplant, except those not requiring immuno-suppressive treatment.

11. Active infection requiring treatment.

12. History of human immunodeficiency virus (HIV) type 1 or 2 antibodies.

13. Known active hepatitis B whose virus load is greater than 500 IU/mL.

14. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class =II), or serious uncontrolled cardiac arrhythmia requiring medication.

15. History or current evidence of any condition, therapy, active infections, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

16. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.

17. Legally incapacitated or has limited legal capacity.

18. Pregnant or breastfeeding.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• AGEN1223
AGEN1223 is a bispecific antibody.
• AGEN1223 and balstilimab
AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.

Locations

Country	Name	City	State
United States	University of Southern California	Los Angeles	California
United States	University of Miami/Sylvester Comprehensive Cancer Center	Miami	Florida
United States	Abramson Cancer Center at the University of Pennsylvania	Philadelphia	Pennsylvania
United States	HonorHealth Research Institute	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Agenus Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	PK parameter correlation to pharmacodynamic assessments	Immune cell subpopulations in blood	Screening up to 1 year of treatment
Other	Characterization of genetic polymorphism of FcyR	In subjects treated with AGEN1223 as single-agent and in combination with balstilimab	Screening up to 2 years of treatment
Other	Biomarkers of pharmacologic activity	Correlation with tumor responses to AGEN1223 and balstilimab treatment	Screening up to 1 year of treatment
Other	Biomarkers in tumor tissue and blood	Correlation with tumor responses to AGEN1223 and balstilimab treatment	Screening up to 1 year of treatment
Other	Median and/or rate of Overall Survival	As defined in the Statistical Analysis Plan	Up to 12 months after last dose
Primary	Dose Limiting Toxicity (DLT)	In subjects in dose escalation	First 28 days of treatment
Primary	Frequency, severity, and duration of treatment-emergent AEs (TEAEs)	For all dose groups according to NCI-CTCAE Version 5.0	Screening through 90 days after last dose
Secondary	Maximum observed concentration at steady state (Cmax-ss)	PK profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Minimum observed concentration at steady state (Cmin-ss)	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Area under the plasma/serum concentration-time curve within time span t1 to t2 at steady-state (AUC(t1-t2)-ss)	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Area under the plasma/serum concentration-time curve from time zero to time t (AUC(0-t))	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Area under the plasma/serum concentration-time curve from time zero to infinity (AUC(0-8))	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Time to maximum observed concentration (tmax)	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	terminal disposition rate constant (?z)	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Terminal elimination half-life (t1/2)	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Systemic clearance (CL)	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Volume of distribution (Vd).	PK Profile of AGEN1223 and balstilimab	From first dose through 2 year of treatment
Secondary	Immunogenicity	Incidence of anti-AGEN1223 antibodies and anti-Balstilimab antibodies	From first dose through 2 year of treatment
Secondary	Overall Response Rate	Per RECIST 1.1 based on Investigator assessment	Screening up to 2 years of treatment
Secondary	Duration of Response	Per RECIST 1.1 based on Investigator assessment	Screening up to 2 years of treatment
Secondary	Disease Control Rate	Including complete and partial responders and stable disease (SD) for at least 12 weeks, per RECIST 1.1 based on Investigator assessment.	Screening up to 2 years of treatment
Secondary	Progression-free Survival median and/or rate	As defined in the Statistical Analysis Plan	Screening up to 2 years of treatment